Project description:Analysis of transcriptional changes after treatment with Palbociclib, PD0325901 or combined treatment in DLD1 (colorectal cancer cell line). The aim of the study was to identify differentially regulated genes after the various treatment, particularly on the downregulated genes as these drugs are inhibitors of the CDK4/6 and MEK pathways and upon inhibition, should lead to the downregulation of pro-tumorigenic genes. Results provide important information on which transcription factors or genes that will be targeted by the inhibition of these 2 pathways
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
Project description:Transcriptional profiling of human mesenchymal stem cells comparing normoxic MSCs cells with hypoxic MSCs cells. Hypoxia may inhibit senescence of MSCs during expansion. Goal was to determine the effects of hypoxia on global MSCs gene expression.
Project description:CDK4/6 inhibitors have emerged in combination with hormone therapy as an effective treatment for HR+/HER2- breast cancer. Despite the clinical success of these drugs, challenges such as varied patient response and acquired resistance remain a significant treatment barrier. To better understand the mechanisms by which breast cancer cells respond to CDK4/6 inhibition, we conducted a multi-omics analysis in T-47D breast cancer cells profiling Palbociclib-induced changes at the gene expression, alternative splicing, and proteomic levels. We report that cell division and proliferation-related genes are often downregulated and also subject to alternative splicing changes. Additionally, we find an upregulation of estrogen response-related genes, suggesting negative feedback between CDK4/6 and upstream hormone signaling. Intriguingly, we observe an upregulation of Cyclin D1 (consistent with previous literature) but not Cyclin D3, indicating distinct and specific roles for these cyclins in the Palbociclib response. Finally, we observe that Palbociclib broadly downregulates genes essential for cell proliferation and survival, and that co-targeting CDK7 in combination additively affects proliferation, suggesting combination strategies which might be used to achieve improved therapeutic benefit. Our findings reveal both the broad patterns and specific gene- and protein-level changes that result from Palbociclib treatment, providing a key resource in understanding the response to CDK4/6 inhibitors for researchers and clinicians to improve breast cancer treatments and expand the use of CDK4/6 inhibitors to other cancers.
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs. One-condition experment, gene expression of 3A6
